Cafoli Lifecare is proud to launch Vonoprazan (20mg) Tablet, a next-generation solution for acid-related disorders. This is a game-changer for our PCD pharma franchise partners, wholesalers, and bulk suppliers looking to dominate the gastroenterology market. As a P-CAB (Potassium-Competitive Acid Blocker), Vonoprazan offers faster, more potent, and longer-lasting acid suppression compared to traditional PPIs, making it a highly preferred choice among medical professionals.
"We invite serious medical business owners, distributors, and hospital suppliers to partner with us for bulk supply, wholesale, and resale of Vonoprazan (20mg) tablets. With its superior efficacy, this product guarantees high demand and ensures a consistent and profitable business for you
Vonopulse 20 Tablet contains Vonoprazan (20 mg), a potent acid suppressant used to treat various gastric acid-related disorders. Vonoprazan belongs to the class of potassium-competitive acid blockers (P-CABs), offering rapid and long-lasting inhibition of gastric acid secretion. Unlike traditional proton pump inhibitors (PPIs), Vonoprazan acts faster, with prolonged efficacy, making it highly effective for conditions requiring acid suppression therapy.
This medication works by blocking the H⁺/K⁺ ATPase enzyme in the stomach lining, reducing acid production without requiring activation by gastric acid. It is widely used for treating gastroesophageal reflux disease (GERD), peptic ulcers, Zollinger-Ellison syndrome, and Helicobacter pylori-associated infections.